ereprof. dr. Gui De Backer
- Work address
-
C. Heymanslaan 10, ingang 42 - verdieping 5
9000 Gent - Guy.DeBacker@UGent.be
Show
Sort by
-
Assessing the probability of risk factor control in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey
-
2021 ESC guidelines on cardiovascular disease prevention in clinical practice
-
Poor adherence to lifestyle recommendations in patients with coronary heart disease : results from the EUROASPIRE surveys
-
Potential for optimizing management of obesity in the secondary prevention of coronary heart disease
-
- Journal Article
- A1
- open access
Treatment goal attainment for secondary prevention in coronary patients with or without diabetes mellitus : Polish multicenter study POLASPIRE
-
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC)
-
- Journal Article
- A1
- open access
INTERASPIRE : an international survey of coronary patients : their cardiometabolic, renal and biomarker status; and the quality of preventive care delivered in all WHO regions in partnership with the World Heart Federation, European Society of Cardiology, Asia Pacific Society of Cardiology, InterAmerican Society of Cardiology, and PanAfrican Society of Cardiology
-
- Journal Article
- A1
- open access
Dyslipidemia management in patients with coronary artery disease : data from the POLASPIRE survey
-
Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test : validation of a new screening algorithm in patients with coronary artery disease from the ESC-EORP EUROASPIRE V registry
-
- Journal Article
- A1
- open access
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019 : a pooled analysis of 1201 population-representative studies with 104 million participants